Nutriband Inc (NTRB) USD0.001

Sell:$5.73Buy:$5.86$0.18 (3.15%)

Prices delayed by at least 15 minutes
Sell:$5.73
Buy:$5.86
Change:$0.18 (3.15%)
Prices delayed by at least 15 minutes
Sell:$5.73
Buy:$5.86
Change:$0.18 (3.15%)
Prices delayed by at least 15 minutes

Company Information

About this company

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Key people

Serguei Melnik
Chairman of the Board, President, Secretary
Gareth Sheridan
Chief Executive Officer, Founder, Director
Gerald Goodman
Chief Financial Officer
Alan Smith
Chief Operating Officer, President of 4P Therapeutics
Jeff Patrick
Chief Scientific Officer
Sergei Glinka
Director
Radu Bujoreanu
Independent Director
Irina Gram
Independent Director
Mark Hamilton
Independent Director
Stefani C. Mancas
Independent Director
Click to see more

Key facts

  • EPIC
    NTRB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US67092M2089
  • Market cap
    $64.47m
  • Employees
    13
  • Shares in issue
    11.15m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.